News from Atom Bioscience

Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia, PA
PRESS RELEASE Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic...
Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia
PRESS RELEASE Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College...
Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA
PRESS RELEASE Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International...
On Gout Awareness Day, Let’s Put the Myths to Rest
PRESS RELEASE On Gout Awareness Day, Let’s Put the Myths to Rest Genetic abnormalities are the real cause...
Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
PRESS RELEASE Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat...
Atom Bioscience to Present at BIO CEO & Investor Conference on February 14, 2022
Lead drug targets unmet medical need in chronic gout Provides significant serum uric acid reduction in...
Atom Bioscience to Present at Biotech Showcase January 10-12, 2022
Lead drug targets unmet medical need in chronic gout Provides significant efficacy without toxic side...
Atom Bioscience Raises $47 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic Diseases
Atom Bioscience Raises $47 Million in Series C Round of Financing to Advance Development of Small Molecule...
Atom Bioscience completes about $30 million in Series B financing
Atom Bioscience is a biopharmaceutical company focusing on the research and development of metabolic...
Atom Bioscience's innovative gout drug has passed the IND application in the United States and carried out phase I clinical research in the United States
Atom Bioscience’s innovative gout drug has passed the IND application in the United States and...

Industry News

Arthritis & Rheumatology: Study Compares Gout Treatments with Different Mechanisms of Action - URAT1 Inhibitor vs Xanthine Oxidase Inhibitor
Arthritis & Rheumatology: Study Compares Gout Treatments with Different Mechanisms of Action –...
Healthline: How Gout Flare-ups May Increase the Risk of Heart Attack, Stroke
Physicians Weekly: Urate-Lowering Treatments Compared for Gout
ATOM_LinkedInBioworldstory
BioWorld: Atom Bioscience Planning Phase III Gout Trial After Encouraging Mid-Stage Readout
BioSpace: Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
Healio.com: 'Horribly mismanaged': Debate over gout treatment rages as cases surge
Gout and Heart Disease: Why You're at Increased Risk
Physicians Weekly: Analyzing the Genetics of Hyperuricemia & Gout in Post-Partum Racial/Ethnic Groups